	US 12,071,479 B2
	Antibodies against ILT2 and use thereof
Ilana Mandel, Manof (IL); Tsuri Peretz, Kiryat Tivon (IL); Dana Haves Ziv, Kibbutz Tuval (IL); Ilana Goldshtein, Misgav (IL); Dror Alishekevitz, Kiryat Tivon (IL); Anna Fridman-Dror, Kibbutz Dalia (IL); Motti Hakim, Kibbutz Gazit (IL); Avidor Shulman, Rakefet (IL); Yair Sapir, Manof (IL); and Tehila Ben-Moshe, Tel Aviv (IL)
Assigned to BIOND BIOLOGICS LTD., Misgav Industrial Park (IL)
Filed by Biond Biologics Ltd., Misgav (IL)
Filed on Aug. 11, 2021, as Appl. No. 17/399,971.
Claims priority of provisional application 63/149,371, filed on Feb. 15, 2021.
Claims priority of provisional application 63/145,604, filed on Feb. 4, 2021.
Claims priority of application No. PCT/IL2020/050889 (WO), filed on Aug. 12, 2020.
Prior Publication US 2022/0048991 A1, Feb. 17, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01); A61K 39/00 (2006.01); A61P 35/00 (2006.01); G01N 33/68 (2006.01)

CPC C07K 16/2803 (2013.01) [A61P 35/00 (2018.01); C07K 16/2818 (2013.01); C07K 16/2863 (2013.01); G01N 33/6854 (2013.01); A61K 2039/505 (2013.01); C07K 2317/34 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)]

23 Claims

1. A monoclonal anti-immunoglobulin-like transcript 2 (ILT2A IgG4 antibody comprising three heavy chain CDRs (CDR-H1-3) and three light chain CDRs (CDR-L1-3), wherein the CDR-H1-3 and CDR-L1-3 comprise

a) SEQ ID NOs: 13-18, respectively,

b) SEQ ID NOs: 1-6, respectively, or

c) SEQ ID NOs: 7-12, respectively, and

wherein the antibody comprises a human IgG4 heavy chain constant region comprising an S228P mutation, an L235E mutation, or both (Eu numbering).